BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test
February 17, 2012
BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
May 17, 2012 / ProteoMonitor - As BG Medicine Submits Cardio Risk Test to FDA, Some Pharmas See Opportunity for Preventive Therapy
January 11, 2012 / Pharmacogenomics Reporter - BG Medicine Partners with Framingham Study to Track Heart Attack Risk
May 1, 2009 / Genome Technology - Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test
April 12, 2013 / ProteoMonitor - Pharmas Nudge Semantic Web Technology Toward Practical Drug Discovery Applications
March 6, 2009 / BioInform